Eli Lilly and Co at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 06:10PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD

Great. Good afternoon, everybody. I'm Terence Flynn, a biopharma analyst at Goldman Sachs. Today, we're very pleased to be hosting Eli Lilly. Joining us from the company is Josh Smiley, the CFO; and Mike Czapar, who's Director of Investor Relations. Thank you both for joining us today. We really appreciate the time.

Questions and Answers:

Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD

Just to start at a high level, COVID-19 has obviously been front and center and is going to have near and long-term impacts on the health care system and companies' business models, if we look at delivery of care, clinical trial conduct or the supply chain. So I would be curious, Josh, to get your take on any preliminary perspectives you could share with respect to the ways which COVID might change your business model or strategy.

Joshua L. Smiley - Eli Lilly and Company - Senior VP & CFO

Sure. Thank you. Thanks, Terence. And thanks for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot